Cost Effectiveness Of Linezolid In Central America

Pfizer

Overview

The therapy with Linezolid (LIN) represents better cost-effectiveness vs. Vancomycin (VAN) for the treatment of nosocomial Pneumonia associate to ventilator (VAP).

Study Type

OBSERVATIONAL

Conditions

Ventilator Acquired Pneumonia

Interventions

LinezolidDRUG

Treatment for VAP as indication approved and as physician criterium.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Evidence of a legally acceptable representative signed and dated informed consent document indicating that him or her has been informed of all pertinent aspects of the study. * Adult (18 years old or older) men and women with confirm diagnosis of VAP treated on ICU with LIN or VAN; on the selected institutions. Exclusion Criteria: * Adult men or women with nosocomial pneumonia not associated to a ventilator.

Outcomes

Primary Outcomes

The rate of resistance Empirical treatment days before specific therapy. Treatment days with Linezolid. Treatment days with Vancomycin.

Time frame: 4 months

Rate of renal failure.

Time frame: 4 months

Rate of healing with Linezolid.

Time frame: 4 months

Rate of healing with Vancomycin.

Time frame: 4 months

Secondary Outcomes

Hospitalization days average with VAN and Linezolid.

Time frame: 4 months

Variation of prices and values among the different institutions.

Time frame: 4 months

The average costs of each intervention.

Time frame: 4 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.